alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
MARYLAND ARMY NATIONAL GUARD (MDARNG) DRINKING 

WATER PFAS SNAPSHOT

The Army National Guard is committed to ensuring quality drinking water is provided to its 

Soldiers, and civilians. Proactive sampling is performed by the Army National Guard on its

drinking water systems, as well as, coordination with other purveyors to ensure perfluorooctane 

sulfonate (PFOS) and perfluorooctanoic acid (PFOA) remains below the Environmental 

Protection Agency (EPA) lifetime health advisory (HA) level of 70 parts per trillion (ppt). The 

EPA HA is not an enforceable or a regulatory standard, and represents a concentration in 

drinking water that is not expected to produce adverse health effects if the water is consumed 

over a lifetime.

Drinking Water Status: Finished drinking water, which is the treated water people drink at 

Camp Fretterd Military Reservation, does not contain PFOS/PFOA above the EPA HA. 

Additionally, Army National Guard-provided drinking water complies with the standards of the 

Safe Drinking Water Act (SDWA), a federal law designed to protect the quality of drinking water 

supplied to the American public. The Army National Guard will continue to monitor on-base 

drinking water to ensure the EPA HA or a properly promulgated state drinking water standard is 

not exceeded.

Test Date: September 2021

PFOA + PFOS Results: 1.66 ppt (J)i

Future Testing Event: September 2024

Type of Drinking Water System: Army National Guard-owned

For Questions Contact: Maryland National Guard State Public Affairs Office

Office Phone Number: 667-296-3662

Office E-mail Address: ng.md.mdarng.list.pao@army.mil

Water quality report: A water quality report is not required for this location

i The reported result is an estimate. Values noted with a ‘J’ flag were detected by the laboratory but the true concentration is 

uncertain.
I 

111TH CONGRESS 

1ST SESSION H. R. 4188 

To authorize appropriations for brownfields site assessment and cleanup, 

and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

DECEMBER 2, 2009 

Mr. SESTAK (for himself, Mr. PALLONE, and Mr. GRIJALVA) introduced the 

following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Transportation and Infrastructure, for a period to be subsequently determined by the Speaker, in 

each case for consideration of such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To authorize appropriations for brownfields site assessment 

and cleanup, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Brownfield Cleanup 

5 Enhancement Act’’. 

6 SEC. 2. BROWNFIELDS SITE ASSESSMENT AND CLEANUP. 

7 Section 104(k)(12) of the Comprehensive Environ8 mental Response, Compensation, and Liability Act of 


jbell on DSKDVH8Z91PROD with BILLS
2 

•HR 4188 IH

1 1980 (42 U.S.C. 9604(k)(12)) is amended to read as fol2 lows: 

3 ‘‘(12) AUTHORIZATION OF APPROPRIATIONS.— 

4 There are authorized to be appropriated to carry out 

5 this subsection $350,000,000 for fiscal year 2010, 

6 $400,000,000 for fiscal year 2011, $450,000,000 for 

7 fiscal year 2012, $500,000,000 for fiscal year 2013, 

8 $550,000,000 for fiscal year 2014, and 

9 $600,000,000 for fiscal year 2015 and each fiscal 

10 year thereafter.’’. 

11 SEC. 3. STATE RESPONSE PROGRAMS. 

12 Section 128(a)(3) of the Comprehensive Environ13 mental Response, Compensation, and Liability Act of 

14 1980 (42 U.S.C. 9628(a)(3)) is amended to read as fol15 lows: 

16 ‘‘(3) FUNDING.—There are authorized to be ap17 propriated to carry out this subsection $70,000,000 

18 for fiscal year 2010, $80,000,000 for fiscal year 

19 2011, $90,000,000 for fiscal year 2012, 

20 $100,000,000 for fiscal year 2013, $110,000,000 for 

21 fiscal year 2014, and $120,000,000 for fiscal year 

22 2015 and each fiscal year thereafter.’’. 

Æ 


jbell on DSKDVH8Z91PROD with BILLS
exhibit10-2.htm


    Exhibit 10.1 

     

    AMENDMENT TO AMENDED AND RESTATED

    CHANGE-IN-CONTROL SEVERANCE AGREEMENT 

     

        THIS AMENDMENT, dated
as of June 1, 2010, by and between SeaChange International, Inc., with its principal place
of business at 50 Nagog Park, Acton, MA 01720 (the “Company”) and William C.
Styslinger, III (the “Executive”). 

     

        WHEREAS, the Company
and the Executive have entered into an Amended and Restated Change-In-Control
Severance Agreement dated as of December 21, 2009 (the
“Agreement”);

     

        WHEREAS, in
recognition of the substantial value provided by the services of Mr. Styslinger
to the Company, it is desired to amend the benefits payable to Mr. Styslinger
pursuant to the Agreement; 

     

        NOW, THEREFORE, in
consideration of the mutual covenants and agreements hereinafter contained and
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Company and the Executive agree as follow:


     

    1. Section 2.2(a) of the Agreement is deleted in its entirety and the
following is substituted in its place: 

     

    “(a) the Company shall pay to the Executive an amount equal to the sum of
(i) three times the Executive’s Base Salary and (ii) the Executive’s Annual
Bonus;” 

     

    2. In all other respects, the Agreement shall remain in full force and
effect. 

     

    [Remainder of Page Intentionally Left Blank] 

     

    

    
    


         IN WITNESS WHEREOF, the undersigned have
caused this instrument to be executed as of the day and year first set forth
above. 

     

    
      	
            	SEACHANGE INTERNATIONAL, INC.	
            
	
            	 	
            
	
            	By:   	/s/ Kevin M. Bisson	
            
	
            	 	Name:  Kevin M. Bisson	
            
	
            	 	Title:    Chief Financial Officer	
            
	 	
            	  	
            
	 	/s/ William C.
      Styslinger, III	
            
	
            	William C. Styslinger, III,
      Individually	
            


    


    2
Exhibit 14 SPEEDUS
CORP. CODE
OF ETHICS FOR
CHIEF EXECUTIVE OFFICER AND SENIOR FINANCE OFFICERS Speedus Corp. (the Company) is committed to
conducting its business in accordance with applicable laws, rules and regulations
and to full and accurate financial disclosure in compliance with applicable
law. This Code of Ethics, applicable to the Companys Chief Executive Officer,
Chief Financial Officer and Controller, or persons performing similar
functions, (collectively, Senior Officers), sets forth specific policies
related to the performance by the Senior Officers of their duties. A Senior Officer must not only comply with applicable
law but also engage in and promote honest and ethical conduct and abide by the
Code of Business Conduct and Ethics and other Company policies and procedures
that govern the conduct of the Companys business. Senior Officers will: 
Act with honesty and integrity, avoiding conflicts
  of interest in their personal and professional relationships.
Provide shareholders with information that is
  accurate, complete, objective, fair, relevant, timely and understandable,
  including in our filings with and other submissions to the U.S. Securities
  and Exchange Commission.
Comply with rules and regulations of federal, state,
  provincial and local governments, and other appropriate private and public
  regulatory agencies.
Treat confidential information acquired in the
  course of ones work as such and not use it for personal advantage.
Not unduly or fraudulently influence, coerce,
  manipulate, or mislead any authorized audit or interfere with any auditor
  engaged in the performance of an internal or independent audit of the Companys
  financial statements or accounting books and records.
Achieve responsible use, control, and stewardship
  over all Company assets and resources that are employed or entrusted to us.
Proactively promote and be an example of ethical
  behavior as a responsible partner among peers, in the work environment and
  the community. If a Senior Officer knows of or suspects a violation
of applicable laws, rules or regulations or this Code of Ethics, such Senior Officer
must immediately report that information to the General Counsel, any member of
the Audit Committee of the Board of Directors or any member of the Board of
Directors. No one will be subject to retaliation because of a good faith report
of a suspected violation. Violations of this Code of Ethics may result in
disciplinary action, up to and including discharge. The Audit Committee of the Board
of Directors shall determine, or shall designate appropriate persons to
determine, appropriate action in response to violations of this Code. If a Senior Officer seeks a waiver of the Code of
Ethics, such Senior Officer must make full disclosure of his particular circumstances
to the General Counsel, the Audit Committee of the Board of Directors or the
Board of Directors. Amendments to and waivers of this Code of Ethics will be
publicly disclosed if and as required by applicable laws and regulations.
Exhibit 32.1 Certification by the Chief Executive Officer pursuant to 18 U.S.C. 1350
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  In connection with the Annual Report of PhytoMedical Technologies, Inc. (the Company) on the Form 10-KSB for the period ending December 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Greg Wujek, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:  (i) the Report filed by the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (ii) The information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of the Company on the dates and for the periods presented therein.  PHYTOMEDICAL TECHNOLOGIES, INC.Date:  March 28, 2008By:/s/ Greg WujekGreg Wujek
President and Chief Executive Officer  This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
[Federal Register Volume 87, Number 3 (Wednesday, January 5, 2022)]
[Notices]
[Page 460]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-28523]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended, and the Determination of the Director, Strategic 
Business Initiatives Unit, Office of the Chief Operating Officer, CDC, 
pursuant to Public Law 92-463. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.

    Name of Committee: Disease, Disability, and Injury Prevention 
and Control Special Emphasis Panel (SEP)--RFA-CE-22-001, Grants to 
Support New Investigators in Conducting Research Related to 
Understanding Polydrug Use Risk and Protective Factors.
    Dates: March 15-16, 2022.
    Times: 8:30 a.m.-5:30 p.m., EDT.
    Place: Web Conference.
    Agenda: To review and evaluate grant applications.
    For Further Information Contact: Aisha L. Wilkes, M.P.H., 
Scientific Review Officer, National Center for Injury Prevention and 
Control, CDC, 4770 Buford Highway NE, Mailstop S106-9, Atlanta, 
Georgia 30341-3717, Telephone: (404) 639-6473, Email: 
<a href="/cdn-cgi/l/email-protection#fdbcaa949196988ebd9e999ed39a928b"><span class="__cf_email__" data-cfemail="ebaabc8287808e98ab888f88c58c849d">[email protected]</span></a>.

    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-28523 Filed 1-4-22; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               MAR-31-1999
<CASH>                                          13,407
<SECURITIES>                                       105
<RECEIVABLES>                                  195,755
<ALLOWANCES>                                    10,713
<INVENTORY>                                    131,889
<CURRENT-ASSETS>                               390,700
<PP&E>                                          56,504
<DEPRECIATION>                                  19,697
<TOTAL-ASSETS>                                 487,615
<CURRENT-LIABILITIES>                          258,930
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           727
<OTHER-SE>                                     126,406
<TOTAL-LIABILITY-AND-EQUITY>                   487,615
<SALES>                                        572,342
<TOTAL-REVENUES>                               572,342
<CGS>                                          329,959
<TOTAL-COSTS>                                  329,959
<OTHER-EXPENSES>                               251,877
<LOSS-PROVISION>                                11,428
<INTEREST-EXPENSE>                               5,315
<INCOME-PRETAX>                               (81,425)
<INCOME-TAX>                                  (29,628)
<INCOME-CONTINUING>                           (51,797)
<DISCONTINUED>                                (19,041)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (70,838)
<EPS-BASIC>                                     (1.02)
<EPS-DILUTED>                                   (1.02)


</TABLE>
Case: 3:17-cv-00275-WHR Doc #: 89 Filed: 10/01/20 Page: 1 of 2 PAGEID #: 2197
(tp - per Judge Rice authorization after his 

review)

Case: 3:17-cv-00275-WHR Doc #: 89 Filed: 10/01/20 Page: 2 of 2 PAGEID #: 2198
<TABLE> <S> <C>

<ARTICLE> 9
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FIRST SHARES
BANCORP, INC. STATEMENTS ENDING SEPTEMBER 30, 2000 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           3,349
<INT-BEARING-DEPOSITS>                               0
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     14,947
<INVESTMENTS-CARRYING>                             605
<INVESTMENTS-MARKET>                               606
<LOANS>                                         74,357
<ALLOWANCE>                                        828
<TOTAL-ASSETS>                                  98,248
<DEPOSITS>                                      86,362
<SHORT-TERM>                                     5,150
<LIABILITIES-OTHER>                                269
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            10
<OTHER-SE>                                       6,457
<TOTAL-LIABILITIES-AND-EQUITY>                  98,248
<INTEREST-LOAN>                                  4,411
<INTEREST-INVEST>                                  882
<INTEREST-OTHER>                                    74
<INTEREST-TOTAL>                                 5,367
<INTEREST-DEPOSIT>                               2,795
<INTEREST-EXPENSE>                               3,098
<INTEREST-INCOME-NET>                            2,269
<LOAN-LOSSES>                                      335
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                  3,110
<INCOME-PRETAX>                                  (787)
<INCOME-PRE-EXTRAORDINARY>                       (787)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (787)
<EPS-BASIC>                                     (1.11)
<EPS-DILUTED>                                   (1.11)
<YIELD-ACTUAL>                                    3.77
<LOANS-NON>                                        287
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                  1,685
<ALLOWANCE-OPEN>                                   549
<CHARGE-OFFS>                                       99
<RECOVERIES>                                        43
<ALLOWANCE-CLOSE>                                  828
<ALLOWANCE-DOMESTIC>                               801
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                             27


</TABLE>
IN THE SUPREME COURT OF TEXAS

- - - - - - - -

NO. 16-0081

CASEY SUTTERFIELD

v.

TERVITA, LLC §

§

§

§

§

§ Dallas County,

5th District.

April 1, 2016

Petitioner's petition for review, filed herein in the above numbered and styled case,

having been duly considered, is ordered, and hereby is, denied.

         

I, BLAKE A. HAWTHORNE

, Clerk of the Supreme Court of Texas, do hereby certify

that the above and attached is a true and correct copy of the orders of the Supreme Court of

Texas in the case numbered and styled as above, as the same appear of record in the minutes of

said Court under the date shown.

It is further ordered that petitioner, CASEY SUTTERFIELD, pay all costs incurred on

this petition.

WITNESS my hand and seal of the Supreme Court of Texas, at the City of Austin, this

the 12th day of May, 2016

.

Blake A. Hawthorne, Clerk

By Monica Zamarripa, Deputy Clerk
Exhibit 99.1 - Certification of Chief Executive Officer


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Muller Media, Inc. (the "Company") on
Form 10-QSB for the period ending September 30, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"). I, John J.
Adams, Chief Executive Officer (or Chief Financial Officer) of the Company,
certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the
Sarbanes- Oxley Act of 2002, that, to the best of my knowledge and belief:

               (1)   The Report fully complies with the requirements of section
                     13(a) or 15(d) of the Securities Exchange Act of 1934; and

               (2)   The information contained in the Report fairly presents, in
                     all material respects, the financial condition and result
                     of operations of the Company.


/s/ John J. Adams
----------------------------
    John J. Adams
    Chief Executive Officer


Date  November 18, 2002
      ---------------
EXHIBIT 31.1

      I, Angela Buffa, certify that:

      1. I have reviewed this quarterly report on Form 10-QSB of OSK CAPITAL II
CORP.;

      2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;

      3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

      4. The registrant's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

      (a) Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the Issuer, including its
consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;

      (b) Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;

      (c) Evaluated the effectiveness of the Issuer's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and

      (d) Disclosed in this report any change in the Issuer's internal control
over financial reporting that occurred during the Issuer's fourth fiscal quarter
ending November 30, 2004 that has materially affected, or is reasonably likely
to materially affect, the Issuer's internal control over financial reporting.

      5. The registrant's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditor and the audit committee of the
registrant's board of directors (or persons performing the equivalent
functions):

      (a) All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and

      (b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal control over
financial reporting.


Dated: November 18, 2005

       /s/ Angela Buffa
       ----------------
       Angela Buffa, Chief Executive Officer